| | Audit Committee | Compensation Committee | Nominating and Corporate Governance Committee | James S. Burns  James S. Burns
President & CEO of AssureRX
James S. Burns became a Director of Vermillion in 2006. He is currently President & CEO of AssureRX, LLC., a personalized medicine company which specializes in pharmacogenetics Prior to joining AssureRX he served as President & CEO of Entremed from June 2004 until December 2008. Mr. Burns was a co-founder and served as President and as Executive Vice President of MedPointe Inc., a specialty pharmaceutical company. From 2000-2001, he served as a founder and Managing Director of MedPointe C... |
|
| | | Robert S. Goggin, III Robert S. Goggin, III
Partner, Keller & Goggin, PC
Mr. Goggin became a Director of Vermillion in March 2013.... |
| | |
| Peter S. Roddy Peter S. Roddy
Vice President and Chief Financial officer of Pain Therapeutics, Inc.
Peter S. Roddy, became a Director of Vermillion in February 2010 and will chair Vermillion’s Audit Committee. He currently is Vice President and Chief Financial officer of Pain Therapeutics, Inc. Prior to his position at Pain Therapeutics, Peter was Senior Vice President Finance and CFO of COR Therapeutics, Inc. He previously held finance positions at MCM Laboratories, Inc., Hewlett-Packard and Price Waterhouse & Company. Peter is currently a member of the Board of Directors of the Ass... |
|
| | | Carl Severinghaus Carl Severinghaus
President of Tecan Americas
Mr. Severinghaus became of Director of Vermillion in March 2010. He has held the position of President of Tecan Americas since 2009. He is responsible for the sales and operations for the Americas Sales Regions, including U.S., Canada, and South America. From 2007 to 2008, he was Senior Vice President of International Sales, responsible for the worldwide sales and operations of the direct and OEM sales channels. Since 2007, he has served as a member to the Executive Committee of Tec... |
| |
|
| William C. Wallen, Ph.D. William C. Wallen, Ph.D.
Former Chief Scientific Officer, Senior Vice President, Research and Development for IDEXX Laboratories
Dr. Wallen became a Director of Vermillion in December 2009. He was formerly the Chief Scientific Officer, Senior Vice President, Research and Development for IDEXX Laboratories. Prior to joining IDEXX Laboratories Dr. Wallen held a number of high level positions with Bayer Healthcare, Diagnostics Division achieving the position of Senior Vice President, Head Officer of Technology. He previously held leadership roles at Becton Dickenson and Wampole Laboratories, a division of Carter-Wa... |
|
|
|
|
|
Financial Expert